Meeting
2018 ASCO Annual Meeting
Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).
Authors
Whitney Paige Kirschbrown
Genentech Inc., South San Francisco, CA
Whitney Paige Kirschbrown , Bei Wang , Ihsan Nijem , Atsushi Ohtsu , Paulo M. Hoff , Manish A. Shah , Lin Shen , Yoon-Koo Kang , Josep Tabernero , Sandhya Girish , Amit Garg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT01774786
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2564)
DOI
10.1200/JCO.2018.36.15_suppl.2564
Abstract #
2564
Poster Bd #
390
Abstract Disclosures
Similar Posters
First Author: Anna Dorothea Wagner
Poster
2017 Gastrointestinal Cancers Symposium
Clinical significance of intratumoral HER2 heterogeneity (IHH) using endoscopic biopsy specimens in patients with HER2-positive gastric cancer (GC) who received T-mab-based chemotherapy.
First Author: Shusuke Yagi
Poster
2016 ASCO Annual Meeting
EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial.
First Author: Anna Dorothea Wagner
Poster
2015 Gastrointestinal Cancers Symposium
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071).
First Author: Markus Hermann Moehler